Can an earthworm enzyme boost stroke recovery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years; * Acute ischemic stroke confirmed by CT or MRI; * Baseline NIHSS score 4-20 at enrollment; * Good prestroke functional status (mRS ≤1); * Randomization within 24 hours of last known well; * Written informed consent provided by the participant or legal representative. Exclusion Criteria: * Received or planned intravenous thrombolysis or endovascular treatment after stroke onset; * Cardioembolic stroke (atrial fibrillation, heart valve replacement, atrial myxoma, endocarditis, etc.); * Other causative etiologies of stroke (aortic dissection, cervico-cerebral arterial dissection, vasculitis, vascular malformation, moyamoya disease/syndrome, fibromuscular dysplasia, etc.); * Non-vascular neurological diseases (intracranial tumor, multiple sclerosis, etc.); * Accompanying hemorrhagic transformation of infarction; * Concomitant use of other fibrinolytic therapy (e.g., urokinase, batroxobin, snake-venom preparations) or anticoagulant therapy (e.g., argatroban, rivaroxaban, dabigatran); * Severe hepatic insufficiency (ALT or AST \>2 × upper limit of normal) or renal insufficiency (creatinine \>1.5 × ULN or eGFR \<40 mL/min/1.73 m²), or coagulopathy, or systemic bleeding, or thrombocytopenia (\<100×10⁹/L); * History of intracranial hemorrhage (e.g., intracerebral hemorrhage or subarachnoid hemorrhage); * Bleeding diathesis or major surgery within 90 days (gastrointestinal bleeding, hemoptysis, etc.); * Hypersensitivity to lumbrokinase or aspirin; * Planned surgery or vascular reconstruction within 90 days that may require study-drug interruption; * History of malignancy or aneurysm (including intracranial or peripheral aneurysm); * Received lumbrokinase or other fibrinolytic therapy within 14 days prior to randomization; * Pregnancy or lactation; * Participation in another clinical trial; * Prior neurological or psychiatric disease that would interfere with neurological assessment; * Expected survival less than 90 days; * Expected inability to complete follow-up.